Zealand Pharma A/S announced positive results from phase 3 trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1). Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks 66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume) In total 9 patients treated with glepaglutide were weaned off parenteral support, while no placebo treated patients were able to wean off parenteral support Glepaglutide treatment was assessed as safe and was well-tolerated in the trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
622.5 DKK | +0.48% | +0.08% | +66.80% |
04/04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
20/03 | Zealand Pharma A/S Approves Appointments to the Board | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.80% | 5.53B | |
-1.68% | 103B | |
+7.43% | 101B | |
+4.40% | 23.07B | |
-11.88% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.78% | 16.94B | |
+6.41% | 14.07B | |
+38.38% | 12.35B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)